^
Association details:
| Biomarker: | EML4-RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | agerafenib (RXDX-105) (BRAF inhibitor, RET inhibitor, CS-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling
Published date:
04/01/2021
Excerpt:
...three novel RET-positive(RET+) patient-derived cancer cell lines, CUTO22(KIF5B-RET+), CUTO32(KIF5B-RET+) and CUTO42(EML4-RET+)...CUTO22 and CUTO42 cell lines were sensitive to the selective RET inhibitors RXDX-105 and BLU-667...CUTO22 and CUTO42 cell lines had <50nM IC50 values for RXDX-105 and BLU-667...
DOI:
10.1124/molpharm.120.000207
